Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Nov;78(9):1170–1174. doi: 10.1038/bjc.1998.649

Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.

Y Ando 1, T Shimizu 1, K Nakamura 1, T Mushiroda 1, T Nakagawa 1, T Kodama 1, T Kamataki 1
PMCID: PMC2062991  PMID: 9820175

Abstract

Bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV), JM216, is the first antineoplastic platinum compound that can be given to patients orally. Several phase II clinical trials of JM216 monotherapy have already been reported. However, no information on the potential drug interactions caused by JM216 is available. In this study, the capacity of JM216 to inhibit cytochrome P450 (CYP) in human liver microsomes was investigated by measuring the inhibition potential (IC50 and Ki) on prototype reactions. Specific substrates of CYP included testosterone (catalysed by CYP3A4), paclitaxel (CYP2C8), 7-ethoxyresorufin (CYP1A1, CYP1A2), coumarin (CYP2A6), aniline (CYP2E1) and (+/-)-bufuralol (CYP2D6). JM216 inhibited the catalytic activities of CYP isozymes. The IC50 values were between 0.3 microM and 10 microM, indicating strong and non-specific inhibitory effects of JM216. The inhibition occurred in a non-competitive manner, and the Ki value was 1.0 and 0.9 microM for metabolite formation of testosterone and paclitaxel respectively. Therefore, some in vivo studies should be conducted to determine whether or not there is a correlation between in vivo and in vitro results.

Full text

PDF
1172

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arlotto M. P., Trant J. M., Estabrook R. W. Measurement of steroid hydroxylation reactions by high-performance liquid chromatography as indicator of P450 identity and function. Methods Enzymol. 1991;206:454–462. doi: 10.1016/0076-6879(91)06114-i. [DOI] [PubMed] [Google Scholar]
  2. Buening M. K., Franklin M. R. The formation of complexes absorbing at 455 nm from cytochrome P-450 and metabloites of compounds related to SKF 525-A. Drug Metab Dispos. 1974 Jul-Aug;2(4):386–390. [PubMed] [Google Scholar]
  3. Chang T. K., Weber G. F., Crespi C. L., Waxman D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 1993 Dec 1;53(23):5629–5637. [PubMed] [Google Scholar]
  4. Cresteil T., Monsarrat B., Alvinerie P., Tréluyer J. M., Vieira I., Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res. 1994 Jan 15;54(2):386–392. [PubMed] [Google Scholar]
  5. First M. R., Schroeder T. J., Weiskittel P., Myre S. A., Alexander J. W., Pesce A. J. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet. 1989 Nov 18;2(8673):1198–1201. doi: 10.1016/s0140-6736(89)91802-3. [DOI] [PubMed] [Google Scholar]
  6. Fukuoka M., Furuse K., Saijo N., Nishiwaki Y., Ikegami H., Tamura T., Shimoyama M., Suemasu K. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst. 1991 Jun 19;83(12):855–861. doi: 10.1093/jnci/83.12.855. [DOI] [PubMed] [Google Scholar]
  7. Guengerich F. P., Dannan G. A., Wright S. T., Martin M. V., Kaminsky L. S. Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or beta-naphthoflavone. Biochemistry. 1982 Nov 9;21(23):6019–6030. doi: 10.1021/bi00266a045. [DOI] [PubMed] [Google Scholar]
  8. Harris J. W., Rahman A., Kim B. R., Guengerich F. P., Collins J. M. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 1994 Aug 1;54(15):4026–4035. [PubMed] [Google Scholar]
  9. Imai Y., Ito A., Sato R. Evidence for biochemically different types of vesicles in the hepatic microsomal fraction. J Biochem. 1966 Oct;60(4):417–428. doi: 10.1093/oxfordjournals.jbchem.a128453. [DOI] [PubMed] [Google Scholar]
  10. Kamataki T., Kitagawa H. Effects of lipid peroxidation on activities of drug-metabolizing enzymes in liver microsomes of rats. Biochem Pharmacol. 1973 Dec 15;22(24):3199–3207. doi: 10.1016/0006-2952(73)90094-4. [DOI] [PubMed] [Google Scholar]
  11. Kelland L. R., Abel G., McKeage M. J., Jones M., Goddard P. M., Valenti M., Murrer B. A., Harrap K. R. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res. 1993 Jun 1;53(11):2581–2586. [PubMed] [Google Scholar]
  12. Marre F., Sanderink G. J., de Sousa G., Gaillard C., Martinet M., Rahmani R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res. 1996 Mar 15;56(6):1296–1302. [PubMed] [Google Scholar]
  13. McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., Look K. Y., Clarke-Pearson D. L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1–6. doi: 10.1056/NEJM199601043340101. [DOI] [PubMed] [Google Scholar]
  14. McKeage M. J., Morgan S. E., Boxall F. E., Murrer B. A., Hard G. C., Harrap K. R. Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates. Cancer Chemother Pharmacol. 1994;33(6):497–503. doi: 10.1007/BF00686508. [DOI] [PubMed] [Google Scholar]
  15. Nakamura K., Yokoi T., Inoue K., Shimada N., Ohashi N., Kume T., Kamataki T. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics. 1996 Oct;6(5):449–457. doi: 10.1097/00008571-199610000-00009. [DOI] [PubMed] [Google Scholar]
  16. Pasanen M., Taskinen T., Iscan M., Sotaniemi E. A., Kairaluoma M., Pelkonen O. Inhibition of human hepatic and placental xenobiotic monooxygenases by imidazole antimycotics. Biochem Pharmacol. 1988 Oct 15;37(20):3861–3866. doi: 10.1016/0006-2952(88)90067-6. [DOI] [PubMed] [Google Scholar]
  17. Pearce R., Greenway D., Parkinson A. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch Biochem Biophys. 1992 Oct;298(1):211–225. doi: 10.1016/0003-9861(92)90115-d. [DOI] [PubMed] [Google Scholar]
  18. Rahman A., Korzekwa K. R., Grogan J., Gonzalez F. J., Harris J. W. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 1994 Nov 1;54(21):5543–5546. [PubMed] [Google Scholar]
  19. Raynaud F. I., Mistry P., Donaghue A., Poon G. K., Kelland L. R., Barnard C. F., Murrer B. A., Harrap K. R. Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol. 1996;38(2):155–162. doi: 10.1007/s002800050464. [DOI] [PubMed] [Google Scholar]
  20. Relling M. V., Nemec J., Schuetz E. G., Schuetz J. D., Gonzalez F. J., Korzekwa K. R. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994 Feb;45(2):352–358. [PubMed] [Google Scholar]
  21. Rose W. C. Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models. Cancer Chemother Pharmacol. 1997;40(1):51–56. doi: 10.1007/s002800050624. [DOI] [PubMed] [Google Scholar]
  22. Ryan D. E., Ramanathan L., Iida S., Thomas P. E., Haniu M., Shively J. E., Lieber C. S., Levin W. Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid. J Biol Chem. 1985 May 25;260(10):6385–6393. [PubMed] [Google Scholar]
  23. Schwartz E. L., Hallam S., Gallagher R. E., Wiernik P. H. Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. Biochem Pharmacol. 1995 Sep 28;50(7):923–928. doi: 10.1016/0006-2952(95)00213-j. [DOI] [PubMed] [Google Scholar]
  24. Testa B., Jenner P. Inhibitors of Cytochrome P-450s and their mechanism of action. Drug Metab Rev. 1981;12(1):1–117. doi: 10.3109/03602538109011082. [DOI] [PubMed] [Google Scholar]
  25. Waxman D. J., Attisano C., Guengerich F. P., Lapenson D. P. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys. 1988 Jun;263(2):424–436. doi: 10.1016/0003-9861(88)90655-8. [DOI] [PubMed] [Google Scholar]
  26. Winzor D. J., Ioannoni B., Reilly P. E. The nature of microsomal monooxygenase inhibition by cimetidine. Biochem Pharmacol. 1986 Jul 1;35(13):2157–2161. doi: 10.1016/0006-2952(86)90586-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES